Keywords: synosia, begins, ph, ii, post-traumatic, stress, trial

Synosia begins Ph II post-traumatic stress trial

Article | 10 November 2008

Print This

Swiss firm Synosia Therapeutics has started a Phase IIa clinical trial with its dopamine b-hydroxylase inhibitor nepicastat (SYN-117) for the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in